Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Total Current Liabilities data on record, last reported at $37.2 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 32.27% year-over-year to $37.2 million; the TTM value through Sep 2025 reached $37.2 million, down 32.27%, while the annual FY2024 figure was $52.7 million, 23.99% down from the prior year.
  • Total Current Liabilities reached $37.2 million in Q3 2025 per ZNTL's latest filing, down from $39.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $69.4 million in Q4 2023 and bottomed at $37.2 million in Q3 2025.
  • Average Total Current Liabilities over 4 years is $52.9 million, with a median of $54.1 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: increased 29.6% in 2023, then tumbled 41.49% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $56.6 million in 2022, then grew by 22.45% to $69.4 million in 2023, then fell by 23.99% to $52.7 million in 2024, then decreased by 29.51% to $37.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $37.2 million in Q3 2025, $39.0 million in Q2 2025, and $49.4 million in Q1 2025.